Literature DB >> 24195047

The outcomes of pars plana vitrectomy without endotamponade for tractional retinal detachment secondary to proliferative diabetic retinopathy.

Rao Muhammad Rashad Qamar1, Muhammad Imran Saleem, Muhammad Farhan Saleem.   

Abstract

AIM: To evaluate the outcomes of pars plana vitrectomy (PPV) without the use of an ocular tamponade in patients having tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy (PDR).
METHODS: It was an interventional study conducted at the Department of Ophthalmology, B.V. Hospital, Bahawalpur, Pakistan, from July 2011 to July 2012. A total of 75 patients (84 eyes) having TRD secondary to PDR were treated by PPV without using an ocular tamponade. All patients included in the study had a tractional retinal detachment secondary to proliferative diabetic retinopathy but didn't have or develop retinal breaks before or during the study period. The surgical procedure included a PPV combined with the removal of the tractional retinal membranes and the application of endolaser photocoagulation to the retina. The mean follow-up period was 12 months.
RESULTS: Successful retinal reattachement was observed in 78 of the operated eyes (92.8%). In these patients, the retina remained attached till the end of the one year follow-up period. Improvement in best corrected visual acuity (BCVA) was seen in 63 eyes (75%). The visual acuity remained unchanged in 9 eyes (10.7%). Mean improvement in BCVA was 2.00+1.24 at baseline to 1.24+1.22 (P<0.05) at the end of the follow-up period.
CONCLUSION: In the absence of the retinal breaks, a TRD secondary to PDR can be successfully treated by pars plana vitrectomy without the use of an ocular tamponade.

Entities:  

Keywords:  endotamponade; pars plana vitrectomy; proliferative diabetic retinopathy; tractional retinal detachment

Year:  2013        PMID: 24195047      PMCID: PMC3808919          DOI: 10.3980/j.issn.2222-3959.2013.05.23

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  22 in total

1.  Vitrectomy for diabetic traction retinal detachment involving the macula.

Authors:  T A Rice; R G Michels; E F Rice
Journal:  Am J Ophthalmol       Date:  1983-01       Impact factor: 5.258

2.  Results of 100 aphakic detachments treated with a temporary balloon buckle: a case against routine encircling operations.

Authors:  H Lincoff; I Kreissig; M Farber
Journal:  Br J Ophthalmol       Date:  1985-11       Impact factor: 4.638

3.  Silicone oil for the treatment of severe proliferative diabetic retinopathy.

Authors:  N D Brourman; M S Blumenkranz; M S Cox; M T Trese
Journal:  Ophthalmology       Date:  1989-06       Impact factor: 12.079

4.  Pars plana vitrectomy and silicone oil injection in proliferative diabetic retinopathy.

Authors:  K Heimann; B Dahl; S Dimopoulos; K D Lemmen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

5.  Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11.

Authors:  G W Abrams; S P Azen; B W McCuen; H W Flynn; M Y Lai; S J Ryan
Journal:  Arch Ophthalmol       Date:  1997-03

6.  The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study.

Authors:  Emily Y Chew; Frederick L Ferris; Karl G Csaky; Robert P Murphy; Elvira Agrón; Darby J S Thompson; George F Reed; Andrew P Schachat
Journal:  Ophthalmology       Date:  2003-09       Impact factor: 12.079

7.  Pars plana lensectomy, pars plana vitrectomy, and silicone oil tamponade as initial management of cataract and combined traction/rhegmatogenous retinal detachment involving the macula associated with severe proliferative diabetic retinopathy.

Authors:  Mark J Douglas; Ingrid U Scott; Harry W Flynn
Journal:  Ophthalmic Surg Lasers Imaging       Date:  2003 Jul-Aug

8.  Extended silicone oil tamponade in primary vitrectomy for complex retinal detachment in proliferative diabetic retinopathy: a long-term follow-up study.

Authors:  Yun-Dun Shen; Chung-May Yang
Journal:  Eur J Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 2.597

9.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

Review 10.  Growth factors in proliferative diabetic retinopathy.

Authors:  Zia Ali Khan; Subrata Chakrabarti
Journal:  Exp Diabesity Res       Date:  2003 Oct-Dec
View more
  5 in total

1.  An optical coherence tomography study of residual subfoveal fluid after successful pars plana vitrectomy in patients with diabetic tractional macular detachment.

Authors:  Mushfig I Karimov; Elmar M Gasymov; Irada J Aliyeva; Lale A Akhundova; Gunay R Rustambayova; Khalid D Aliyev
Journal:  Eye (Lond)       Date:  2018-05-23       Impact factor: 3.775

2.  Characteristics and outcomes of vitrectomy for proliferative diabetic retinopathy in young versus senior patients.

Authors:  Mengyu Liao; Xiaohong Wang; Jinguo Yu; Xiangda Meng; Yuanyuan Liu; Xue Dong; Jianan Li; Rodrigo Brant; Bo Huang; Hua Yan
Journal:  BMC Ophthalmol       Date:  2020-10-19       Impact factor: 2.209

3.  A prospective study on postoperative discomfort after 20-gauge pars plana vitrectomy.

Authors:  Ji-Guo Yu; Fang Ni; Yi Xiang; Yi-Fan Feng; Jue Wang; Xun-An Fu
Journal:  Clin Ophthalmol       Date:  2015-07-24

4.  Advantages of diabetic tractional retinal detachment repair.

Authors:  Amir Sternfeld; Ruth Axer-Siegel; Hadas Stiebel-Kalish; Dov Weinberger; Rita Ehrlich
Journal:  Clin Ophthalmol       Date:  2015-10-23

5.  Clinical Analysis of Persistent Subretinal Fluid after Pars Plana Vitrectomy in Macula with Diabetic Tractional Retinal Detachment.

Authors:  Yong-Koo Kang; Jae-Pil Shin
Journal:  J Clin Med       Date:  2021-12-17       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.